SCHEMBL4598754

SCHEMBL4598754

N=C(N)NCCC[C@H](N)C(=O)OC[N+](=O)[O-]

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 3/20 0.37
▸ NOS3 P29474 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ NPY4R P50391 5/20 0.35
▸ NPY1R P25929 3/20 0.35
▸ OTC P00480 1/20 0.33
▸ DPP7 Q9UHL4 1/20 0.33
▸ NPY2R P49146 2/20 0.32
▸ NPY5R Q15761 2/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ DDAH1 O94760 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203673 0.84 NOS1 (0.38) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL13396391 0.84 NOS1 (0.34) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL27681071 0.83 NOS1 (0.37) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL13396344 0.81 CA12 (0.36) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL8414057 0.80 NPY4R (0.38) NPY4RNPY1ROTCDPP7NPY2R
SCHEMBL11897923 0.80 NPY4R (0.38) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL13396394 0.80 CA12 (0.36) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL13396449 0.80 CA12 (0.36) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL7776928 0.80 NOS1 (0.37) NOS1NOS3NOS2NPY4RNPY1R
SCHEMBL9237239 0.80 NPY4R (0.39) NOS1NOS3NOS2NPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220347212-A1 PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS CHILDREN'S MEDICAL CENTER CORPORATION 2022-11-03 — — US disclosed
EP-3962365-A1 PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-09 — — EP disclosed
WO-2020222866-A1 PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-11-05 — — WO disclosed
EP-1058725-B1 USE OF BACTERIA ENDOWED WITH ARGININE DEIMINASE TO INDUCE APOPTOSIS AND/OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL OR DIETETIC COMPOSITIONS CONTAINING SUCH BACTERIA ACTIAL FARMACEUTICA LDA (PT) 2008-04-09 — — EP disclosed
US-7147847-B2 Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria VSL PHARMACEUTICALS, INC. (US) 2006-12-12 — — US disclosed
US-20030215429-A1 Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria MENDES S.R.L. (IT) 2003-11-20 — — US disclosed
US-6572854-B1 Lactobacillus brevis MENDES S.R.L. (IT) 2003-06-03 — — US disclosed
Send feedback